logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Canada Attempts Biosimilar Balancing Act

March 2, 2017
-
Publications
-
Posted by MORSE Team - < 1 min read.

Pink Sheet Pharma Intelligence published the attached article by Francesca Bruce on February 17, 2017.  The article provides a helpful summary of the current pan-Canadian Pharmaceutical Alliance (pCPA) Biologics/Biosimilar Consultations.  We thank Ms. Bruce for seeking our perspective on this topic and Pink Sheet for granting permission to post this article.

 

A copy of the article can be downloaded here.

 

Source article on Pink Sheet

 

To receive timely industry updates and insights please be sure to sign up for Market Access Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
pCPA
← PREVIOUS POST
The pan-Canadian Cancer Drug Funding Sustainability Initiative
NEXT POST →
Terms of Reference for Scientific Advisory Panel on Opioid Use and Contraindications

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2021 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Canada Attempts Biosimilar Balancing Act
Private
Public
Private

INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB

Public
INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB
Public
Private
Public
INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB
Private

INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB